AMBER THERAPEUTICS HOLDINGS LIMITED
ActiveKey figures
AMBER THERAPEUTICS HOLDINGS LIMITED does not disclose its turnover in its latest accounts; the profit for the year is as stated in the accounts.
Ratios
2025Sector comparison
SIC 72110Where the company stands among the 3,991 active companies whose first SIC code is 72110 (Research and experimental development on biotechnology).
- BRACCO HORIZONS LIMITED£526.1m
- TAURX THERAPEUTICS MANAGEMENT LTD.£470.3m
- LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED£317m
- JAZZ PHARMACEUTICALS RESEARCH UK LIMITED£289.2m
- GENOME RESEARCH LIMITED£273.7m
- MODERNA BIOTECH UK LIMITED£236.5m
- CURIA (SCOTLAND) LIMITED£183m
- ASTEX THERAPEUTICS LIMITED£163.6m
- HORIZON DISCOVERY GROUP LIMITED£159.6m
- AMGEN LIMITED£134.4m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 3,991. The line on each bar marks the median.
Summary: AMBER THERAPEUTICS HOLDINGS LIMITED
What kind of company is it?
AMBER THERAPEUTICS HOLDINGS LIMITED is a private limited company registered with Companies House under company number 13089338. It was incorporated on 18 Dec 2020. Its status is active. The registered office is in Didcot (OX11). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).
How is the company doing financially?
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files group accounts. Loss for the year was £28,312,696. Net assets were £7,709,069, down 63.6% on the previous year. Cash at bank and in hand was £94,069. Total assets were £7,709,152 and total liabilities £83. The company had an average of 0 employees. Figures are available for 5 financial years (2021–2025).
How does it compare with similar companies?
Compared with 3,991 active companies whose first SIC code is 72110: By net assets it ranks higher than 95% of them (median £20,978). By total assets it ranks higher than 91% of them (median £125,654). By cash it ranks lower than 51% of them (median £101,976). By number of employees it ranks lower than 65% of them (median 1). It is older than 53% of them (median age 5.4 years).
Has it received government grants?
It is recorded as the recipient of 2 central government grants worth £664.5k, mainly from Department for Business, Energy and Industrial Strategy.
Who runs and controls the company?
The company has 6 current directors. One person with significant control is registered.
When are its next filings due?
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 31 Dec 2026.
Filed accounts2021–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Profit for the year | — | — | -1,988,368 | -2,659,202 | -28,312,696 |
| Cash at bank and in hand | 498,684 | 194,670 | 2,295,352 | 164,652 | 94,069 |
| Total assets | 502,723 | 200,330 | 6,198,167 | 21,208,245 | 7,709,152 |
| Total liabilities | 5,608 | 6,255 | 7,951,583 | 1,238 | 83 |
| Net assets / total equity | 499,108 | 196,977 | -1,753,416 | 21,207,007 | 7,709,069 |
| Average number of employees | 2 | 2 | 6 | 0 | 0 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025Research and experimental development on biotechnology
As described in the company's latest filed accounts.
Government grants
2 grantsAMBER THERAPEUTICS HOLDINGS LIMITED is recorded as the recipient of 2 central government grants since 2021, together worth £664.5k.
- Department for Business, Energy and Industrial Strategy
- 1 grant · £553.7k
- Department for Science, Innovation and Technology
- 1 grant · £110.7k
- Amber-UI: A closed-loop bioelectronic system for urinary incontinenceDepartment for Business, Energy and Industrial Strategy · £553,733 · UKRI - Innovate - Scheme 21/22
- Amber-UI: A closed-loop bioelectronic system for urinary incontinenceDepartment for Science, Innovation and Technology · £110,746 · UKRI - Innovate UK - Scheme
From the Government Grants Register published by the Cabinet Office (financial years 2016/17 onwards, Open Government Licence v3.0). It covers grants from central government departments and their agencies where the register states the recipient's company number and the recipient name matches this company; grants from local authorities, lottery distributors and devolved governments are not included.
History
22 events- Financial year 2025 endedAccounts: net assets £7.7m, 0 employees
- Oxford Science Enterprises Holdings Ii Limited registered as a person with significant control
- Oxford Science Enterprises Plc ceased to be a person with significant control
- David Rogers AMERSON appointedDirector
- Financial year 2024 endedAccounts: net assets £21.2m, 0 employees
- Name changed to AMBER THERAPEUTICS HOLDINGS LIMITEDPreviously AMBER THERAPEUTICS LTD
- Tim DENISON resignedDirector
- Caroline BUTLER appointedDirector
Earlier events (14)
- Yen-Min Kevin CHU appointedDirector
- Tiffany LE appointedDirector
- Oxford Science Enterprises Plc registered as a person with significant control
- Jonathan Martin GLENN resignedDirector
- Financial year 2023 endedAccounts: net assets −£1.8m, 6 employees
- Jonathan Martin GLENN appointedDirector
- Financial year 2022 endedAccounts: net assets £197k, 2 employees
- Financial year 2021 endedAccounts: net assets £499.1k, 2 employees
- Liliane CHAMAS appointedDirector
- Tim DENISON appointedDirector
- Aidan Harold Winston Crawley ceased to be a person with significant control
- Aidan Harold Winston CRAWLEY appointedDirector
- Aidan Harold Winston Crawley registered as a person with significant control
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.